Diploma (LON:DPLM - Get Free Report) announced its quarterly earnings results on Wednesday. The company reported GBX 80.20 ($1.09) earnings per share for the quarter, Digital Look Earnings reports. Diploma had a net margin of 9.25% and a return on equity of 13.18%.
Diploma Trading Down 0.5%
Shares of Diploma stock traded down GBX 25.63 ($0.35) during trading on Monday, reaching GBX 4,738.37 ($64.12). 416,963 shares of the stock were exchanged, compared to its average volume of 452,543. The company has a quick ratio of 0.80, a current ratio of 2.17 and a debt-to-equity ratio of 62.17. The firm has a market cap of £6.32 billion, a price-to-earnings ratio of 54.47, a price-to-earnings-growth ratio of 2.82 and a beta of 0.75. Diploma has a 1 year low of GBX 3,532 ($47.79) and a 1 year high of GBX 5,025 ($68.00). The stock's fifty day moving average is GBX 3,999.40 and its 200 day moving average is GBX 4,261.
Insider Activity at Diploma
In related news, insider David S. Lowden acquired 750 shares of the firm's stock in a transaction on Friday, March 21st. The stock was acquired at an average cost of GBX 3,928 ($53.15) per share, for a total transaction of £29,460 ($39,864.68). Also, insider Katie Bickerstaffe purchased 44 shares of Diploma stock in a transaction that occurred on Wednesday, May 21st. The shares were bought at an average price of GBX 4,867 ($65.86) per share, for a total transaction of £2,141.48 ($2,897.81). Insiders have acquired a total of 1,346 shares of company stock worth $5,393,173 in the last 90 days. Company insiders own 0.52% of the company's stock.
About Diploma
(
Get Free Report)
Diploma PLC, together with its subsidiaries, supplies specialized technical products and services in the United Kingdom, Continental Europe, North America, and internationally. It operates through three business sectors: Life Sciences, Seals, and Controls. The Life Sciences sector supplies technology-enabled products used in surgical procedures in operating theatres and endoscopy; testing equipment and services for clinical laboratories; and bio-pharma, food safety and testing, and other research-oriented products.
Featured Stories
Before you consider Diploma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Diploma wasn't on the list.
While Diploma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
